The brief · 2 July 2026
Two pharma giants and a Microsoft mega-subsidiary today: AI settles into the labs while Redmond doubles down on the enterprise.
A pharma giant is handing part of its research to an AI platform instead of keeping it inside its own labs. If it works, the time between a drug idea and clinical testing shrinks, which matters to you the day you are waiting for a treatment that does not exist yet.
practitioners › Deal announced July 2, 2026, Insilico Medicine's Pharma.AI platform, potential value up to 600 million dollars.
Insilico Medicine →Microsoft Frontier Company will help large enterprises deploy AI on their own data, backed by $2.5 billion. If you're just casually using ChatGPT, this doesn't touch you directly. But it signals where the money's flowing: more toward enterprise integration than consumer-facing tools.
practitioners › First partnership announced: LSEG (London Stock Exchange Group), enabling natural-language queries over structured and unstructured financial data inside LSEG Workspace.
Microsoft →